anti-TIGIT + pomalidomide + dexamethasone

This is a combination therapy consisting of an anti-TIGIT monoclonal antibody, pomalidomide, and dexamethasone. Anti-TIGIT antibodies are immune checkpoint inhibitors that block the T cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on T cells and natural killer (NK) cells, thereby enhancing anti-tumor immune responses by preventing inhibitory signaling mediated by TIGIT's interaction with its ligands such as CD155[1][2][3][4]. Pomalidomide is an immunomodulatory small molecule that enhances T cell and NK cell function and has direct antitumor effects; it is approved for use in multiple myeloma[6][8]. Dexamethasone is a synthetic glucocorticoid corticosteroid used to reduce inflammation and modulate immune responses. The combination aims to synergistically enhance antitumor immunity—anti-TIGIT relieves immune suppression, pomalidomide stimulates immune effector cells, and dexamethasone manages inflammation or side effects. This regimen is primarily being investigated for hematologic malignancies such as multiple myeloma.

Other names

anti-TIGIT + pomalidomide + dexamethasoneBMS-986207 + pom + dex